文献速递肾小球疾病

首个南亚前瞻性纵向观察性IgA肾病队列的三年临床结局

Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort.
PubMed 文献 · Kidney Int Rep · 2021-11-24

GRACE-IgANI是首个南亚前瞻性IgA肾病队列,201例中195例完成3年随访,均接受优化支持治疗,高危者接受全身糖皮质激素。39.4%患者3年内快速进展,36.9%发生复合结局,6个月时MEST-T2评分、24小时尿蛋白≥1 g/d、eGFR<60及eGFR年下降≥5为复合结局显著预测因素。

要点

  • 3年内39.4%患者eGFR年下降≥5 ml/min/1.73 m2,36.9%发生复合结局。
  • 6个月时MEST-T2评分、尿蛋白≥1 g/d、eGFR<60及eGFR年下降≥5预测复合结局。
  • 各随访点尿蛋白<1 g/d显著延迟复合结局时间。

核心结论

  • 除基线组织学外,6个月时测定的纵向临床变量和肾活检后eGFR年下降≥5 ml/min/1.73 m2是复合结局的重要预测因素。

研究设计与样本

  • GRACE-IgANI是首个南亚前瞻性IgA肾病队列,预设目标、方案化纵向随访并广泛采集生物样本。
  • 201例中195例(97%)于2020年9月完成3年随访。
  • 所有患者接受优化支持治疗,进展高危者接受全身糖皮质激素。

主要发现

  • 193例中76例(39.4%)3年内快速进展,即eGFR每年下降≥5 ml/min/1.73 m2。
  • 195例中72例(36.9%)3年内发生复合结局,定义为eGFR下降≥50%、eGFR<15 ml/min/1.73 m2、开始肾脏替代治疗或死亡。
  • 各预定随访点达到尿蛋白<1 g/d显著延迟复合结局时间。
  • eGFR年均下降≥5 ml/min/1.73 m2预测3年复合结局的敏感度86%、特异度89%,自1年起判别良好(AUC 0.8,SE 0.04,95%CI 0.7-0.9,P<0.0001)。
  • Cox比例风险模型显示复合结局显著预测因素:基线MEST-T2评分(HR 3.3,95%CI 1.7-6.5,P<0.001)、6个月时24小时尿蛋白≥1 g/d(HR 2.1,95%CI 1.1-3.9,P=0.02)、eGFR<60 ml/min/1.73 m2(HR 2.9,95%CI 1.1-7.6,P=0.03)、eGFR年下降≥5 ml/min/1.73 m2(HR 2.7,95%CI 1.6-4.8,P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glomerular Research And Clinical Experiments-IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgA nephropathy (IgAN) cohort with prespecified objectives, protocolized longitudinal follow-up, and extensive biosample collection. The baseline risk scores predicted high risk of kidney disease progression. METHODS: A total of 195 of 201 patients (97%) completed 3-year follow-up in September 2020. All patients received optimized supportive care, and those at high risk of progression were offered systemic corticosteroids. RESULTS: A total of 76 patients (76 of 193, 39.4%) had rapid progression in 3 years (≥5 ml/min per 1.73 m2 decline in estimated glomerular filtration rate [eGFR] per year). A total of 72 patients (72 of 195, 36.9%) experienced the composite outcome (CO), defined as ≥50% fall in eGFR, eGFR < 15 ml/min per 1.73 m2, commenced kidney replacement therapy or death, in 3 years. At each scheduled follow-up, achievement of proteinuria level < 1 g/d significantly delayed the time to the CO. The receiver operating characteristic curve of average annual decline in eGFR ≥ 5 ml/min per 1.73 m2 had 86% sensitivity and 89% specificity for CO in 3 years and had good discrimination from 1 year onwards (area under the curve 0.8, SE 0.04, 95% CI 0.7-0.9, P < 0.0001). The significant predictors of CO by Cox proportional-hazards model were as follows: baseline MEST-T2 score (hazard ratio [HR] 3.3, 95% CI 1.7-6.5, P < 0.001), along with 24-hour urine protein level ≥ 1 g/d (HR 2.1, 95% CI 1.1-3.9, P = 0.02), eGFR < 60 ml/min per 1.73 m2 (HR 2.9, 95% CI 1.1-7.6, P = 0.03), and rate of eGFR decline ≥ 5 ml/min per 1.73 m2/yr (HR 2.7, 95% CI 1.6-4.8, P < 0.001) all measured at 6 months. Mortality was 11 of 195 (5.6%). CONCLUSION: We identified longitudinal clinical variables measured at 6 months and ≥5 ml/min per 1.73 m2 annual fall in eGFR after kidney biopsy as important predictors for composite outcome in addition to baseline histology.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Alexander S, Varughese S, Franklin R, et al. Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort. Kidney Int Rep. 2021. PMID: 35155869. doi:10.1016/j.ekir.2021.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。